Besides the acute phase gastrointestinal effects which may lead to up to 10% of people discontinuing the drugs, there are other potential GI side effects of obstruction, excessive loss of muscle mass, and potentially association with some eye disease adverse events
Consequently, they have emerged as promising candidates for a new generation of tumor imaging and therapeutic agents of various CD38-expressing malignancies [85, 88]
WADA Prohibition The World Anti-Doping Agency explicitly prohibits AOD-9604 for competitive athletes: Listed under Section S0 (Non-Approved Substances) and S2.2.3 (Growth Hormone Fragments) Prohibited at all times (both in-competition and out-of-competition) No Therapeutic Use Exemptions (TUEs) available Detection methods developed and implemented in anti-doping laboratories worldwide WADAs 2013 statement clarified that AOD-9604 is a substance still under pre-clinical and clinical development and has not been approved for therapeutic use by any government health authority in the world. Research Classification: AOD-9604 is available only for laboratory research use
Injection frequency: AOD 9604 requires daily injection
Designed for comprehensive metabolic protocols, this premium formulation targets the NNMT enzyme to investigate simultaneous pathways of fat metabolism, muscle quality improvement, and cellular rejuvenation